1. Introduction {#sec1-marinedrugs-15-00363}
===============

Marine-derived peptides with a hybrid biosynthetic pathway, non-ribosomal peptide synthetases (NRPSs) and polyketide synthetases (PKSs), always show diverse chemicals and activities \[[@B1-marinedrugs-15-00363],[@B2-marinedrugs-15-00363],[@B3-marinedrugs-15-00363]\]. These peptides provide many prophylactic and curative medicinal drugs with wide bioactivities such as antimalarial, antitumor, antimicrobial, antiviral, and cardioprotective actions \[[@B4-marinedrugs-15-00363],[@B5-marinedrugs-15-00363],[@B6-marinedrugs-15-00363]\]. Efforts by many research groups focusing on hybrid peptides from marine organisms have been rewarded by the discoveries of novel and bioactive compounds, and some of them have been clinically studied and approved by FDA for disease treatments. For example, the linear peptides E7974 \[[@B7-marinedrugs-15-00363]\], ASG-5ME \[[@B8-marinedrugs-15-00363]\], SGN-75 \[[@B9-marinedrugs-15-00363]\], and CDX-011 \[[@B10-marinedrugs-15-00363]\], cyclic peptide elisidepsin \[[@B11-marinedrugs-15-00363]\], and aplidine \[[@B12-marinedrugs-15-00363]\] are anticancer agents within Stages I--III clinical trials. Besides, SGN-35 \[[@B13-marinedrugs-15-00363]\] and ziconotide \[[@B14-marinedrugs-15-00363],[@B15-marinedrugs-15-00363]\], semi-synthetic and natural peptides for the treatment of cancer and pain, respectively, have been approved by FDA. It has been illustrated that marine-derived peptides with NRPS/PKS biosynthetic pathway may have the great potential as lead compounds for drug development.

During our research on bioactive metabolites of marine organisms collected from the South China Sea, several bioactive peptides have been isolated from the fungi derived from corals \[[@B16-marinedrugs-15-00363],[@B17-marinedrugs-15-00363],[@B18-marinedrugs-15-00363],[@B19-marinedrugs-15-00363]\]. Recently, chemical investigation of the culture of marine-derived fungus *Aspergillus versicolor* (TA01-14) isolated from a gorgonian *Carijoa* sp. resulted in the isolation of a new centrally symmetrical NRPS/PKS-derived cyclohexapeptide, aspersymmetide A (**1**), and a known peptide, asperphenamate (**2**) \[[@B20-marinedrugs-15-00363]\] ([Figure 1](#marinedrugs-15-00363-f001){ref-type="fig"}). Herein, we report the isolation, structure elucidation, and biological evaluation of these compounds.

2. Results and Discussion {#sec2-marinedrugs-15-00363}
=========================

Aspersymmetide A (**1**) was obtained as a white powder. (+)-HRESIMS of **1** gave \[M + H\]^+^ and \[M + Na\]^+^ at *m*/*z* 727.3245 and 749.3062, respectively, indicating a molecular formula of C~42~H~42~N~6~O~6~ with 25 degrees of unsaturation. The ^1^H NMR spectrum ([Table 1](#marinedrugs-15-00363-t001){ref-type="table"}) exhibited two amide (NH) protons at *δ*~H~ 12.23 and 9.10, two *α*-protons of amino acids at *δ*~H~ 5.24 and 4.47, one 1,2-disubstituted benzene ring and one mono-substituted benzene ring (*δ*~H~ 6.83--7.89). The ^13^C NMR spectrum revealed the presence of three amide carbonyls at *δ*~C~ 169.8, 168.4, and 167.1, twelve aromatic carbons at *δ*~C~ 140.2, 138.3, 132.0, 129.6 (2C), 127.6 (2C), 127.5, 125.8. 121.2, 117.9, and 115.1, and three nitrogen-bearing carbons at *δ*~C~ 60.5, 51.6, and 46.7.

Detailed analysis of 1D and 2D NMR data led to the identification of three units including a proline (Pro.), a phenylalanine (Phe.), and an anthranilic acid (AA) ([Figure 2](#marinedrugs-15-00363-f002){ref-type="fig"}a). However, these three units only were attributed to be half of the proposed molecular formula. It suggested that **1** should be a symmetrical dimer. The HMBC correlations were used to connect the residues in **1**. The correlations \[Phe-NH→AA-CO\] and \[AA-NH→Pro-CO\] revealed the half sequence of CO-Phe-NH→CO-AA-NH→CO-Pro-N ([Figure 2](#marinedrugs-15-00363-f002){ref-type="fig"}). The \[Pro-α-H→Phe-CO\] connected the two half sequences to establish the whole cyclic structure, cyclo-\[CO-Phe--AA--Pro--Phe--AA--Pro-N\]. Additional evidence confirmed the structure of **1** on the basis of the ESI MS^2^ experiments with neutral losses ([Figure 3](#marinedrugs-15-00363-f003){ref-type="fig"} and [Figure S14](#app1-marinedrugs-15-00363){ref-type="app"}). Thus, the planar structure of **1** was determined as shown in [Figure 2](#marinedrugs-15-00363-f002){ref-type="fig"}b.

The absolute configurations of the amino acids in **1** were determined by UPLC-MS analysis of the acid hydrolysate derivatized with Marfey's reagent (*N*^α^-(2,4-dinitro-5-fluorophenyl)-[l]{.smallcaps}-alalinamide, [l]{.smallcaps}-FDAA) \[[@B21-marinedrugs-15-00363]\]. The retention times and negative ESIMS indicated the presence of [l]{.smallcaps}-Pro and [l]{.smallcaps}-Phe in **1** (see Experimental and [Figure S16](#app1-marinedrugs-15-00363){ref-type="app"}). Thus, the absolute configuration of **1** was determined as shown in [Figure 1](#marinedrugs-15-00363-f001){ref-type="fig"}. These structural features revealed that aspersymmetide A (**1**) is a centrally symmetric cyclohexapeptide.

Centrosymmetric cyclopeptides (CSCs) are an important class of peptides that always show diverse bioactivities, such as the enniatins \[[@B22-marinedrugs-15-00363]\] with antibiotic, antifungal, antiinsectan, and cytotoxic activities, and PF1022 \[[@B23-marinedrugs-15-00363]\] with anthelmintic activity. Particularly, fusafungine \[[@B24-marinedrugs-15-00363]\], a mixture of enniatins, has been an active agent used in antibiotics for treatment of nasal and throat infection; emodepdide, the bis-para morpholino-PF1022A, has been introduced into the market as a broad spectrum anthelmintic \[[@B25-marinedrugs-15-00363]\]. A literature survey revealed that the majority of CSCs are synthetic \[[@B26-marinedrugs-15-00363],[@B27-marinedrugs-15-00363],[@B28-marinedrugs-15-00363],[@B29-marinedrugs-15-00363]\], while only a few have been found in natural sources, including cyclohexadepsipeptides (**3**--**10**) \[[@B22-marinedrugs-15-00363],[@B30-marinedrugs-15-00363],[@B31-marinedrugs-15-00363],[@B32-marinedrugs-15-00363],[@B33-marinedrugs-15-00363],[@B34-marinedrugs-15-00363],[@B35-marinedrugs-15-00363],[@B36-marinedrugs-15-00363],[@B37-marinedrugs-15-00363],[@B38-marinedrugs-15-00363],[@B39-marinedrugs-15-00363],[@B40-marinedrugs-15-00363]\] and cyclooctadepsipeptides (**11**--**14**) \[[@B25-marinedrugs-15-00363],[@B34-marinedrugs-15-00363],[@B41-marinedrugs-15-00363],[@B42-marinedrugs-15-00363],[@B43-marinedrugs-15-00363],[@B44-marinedrugs-15-00363]\] ([Table 2](#marinedrugs-15-00363-t002){ref-type="table"}, [Figure S17](#app1-marinedrugs-15-00363){ref-type="app"}). Compounds **3**--**13** were obtained from terrestrial microorganisms, and **14** was isolated from the marine-derived bacterium *Micromonospora* sp. aspersymmetide A (**1**) represents the first example of centrally symmetric cyclohexapeptide from marine organisms.

Aspersymmetide A (**1**) was evaluated for brine shrimp lethality against *Artemia salina*, for cytotoxicity against the human breast cancer (MCF-7), human pulmonary carcinoma (NCI-H292), and human skin squamous carcinoma (A-431) cell lines, for antibacterial activity against *Staphylococcus albus* and *Escherichia coli*, for antiviral activity against the human cytomegalovirus (HCMV) and herpes simplex virus (HSV-1), and for enzymic inhibition toward acetyl cholinesterase (AChE), Top I, and *α*-glucosacharase. It displayed weak cytotoxicity against NCI-H292 and A431 cells with an inhibition ratio of 53.84% and 63.62% at a concentration of 10 μM (adriamycin, 1 μM, 93.36% and 91.00%). However, **1** was inactive in other bioassays.

3. Materials and Methods {#sec3-marinedrugs-15-00363}
========================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-15-00363}
------------------------------------

Optical rotations were measured on a JASCO P-1020 digital polarimeter (JASCO Ltd., Tokyo, Japan). IR spectra were recorded on a Nicolet-Nexus-470 spectrometer (Perkin Elmer Ltd., Boston, MA, USA) using KBr pellets. NMR spectra were recorded on a JEOL JEM-ECP NMR spectrometer (JEOL Ltd., Tokyo, Japan; 500 MHz for ^1^H and 125 MHz for ^13^C), using TMS as internal standard. The ESIMS spectra were obtained from a Micromass Q-TOF spectrometer (Waters Ltd., Boston, MA, USA). Semi-preparative HPLC was performed on a Hitachi L-2000 system (Hitachi Ltd., Tokyo, Japan) using a C18 column (Kromasil (Eka Ltd., Bohus, Sweden) 250 × 10 mm, 5 μm, 2.0 mL/min). UPLC-MS was performed on Waters UPLC^®^ system (Waters Ltd., Boston, MA, USA) using a C18 column (ACQUITY UPLC^®^ (Waters Ltd., Boston, MA, USA) BEH C18, 2.1 × 50 mm, 1.7 μm; 0.5 mL/min) and ACQUITY QDa ESIMS scan from 150 to 1000 Da. Silica gel (Qingdao Haiyang Chemical Group Co., Qingdao, China; 200--300 mesh), octadecylsilyl silica gel (YMC Co., Ltd., Tokyo, Japan; 45--60 μm), and Sephadex LH-20 (GE Ltd., Hartford, CT, USA) were used for column chromatography (CC). Precoated silica gel plates (Yantai Zhifu Chemical Group Co., Yantai, China; G60, F-254) were used for thin layer chromatography.

3.2. Fungal Material {#sec3dot2-marinedrugs-15-00363}
--------------------

The fungus *Aspergillus versicolor* (TA01-14) was isolated from a gorgonian *Carijoa* sp. (GX-WZ-2010001) collected from the Weizhou coral reefs in the South China Sea in April 2010. The strain was deposited at the Key Laboratory of Marine Drugs, the Ministry of Education of China, School of Medicine and Pharmacy, Ocean University of China, Qingdao, China, with the Genbank (NCBI) accession number KP759287.

3.3. Fermentation, Extraction, and Isolation {#sec3dot3-marinedrugs-15-00363}
--------------------------------------------

The fungus was cultured on rice solid medium (fifty 1000 mL Erlenmeyer flasks, each containing 50 g of rice and 50 mL of sea water) at room temperature. After 60 days of cultivation, the fermented rice substrate was extracted three times with ethyl acetate (EtOAc) (200 mL per flask) to give an organic extract (10 g). The extract was subjected to a silica gel column chromatography (CC) and eluted by a gradient of petroleum ether (PE)--EtOAc (PE, 100%--0), EtOAc--MeOH (*v:v*, 9:1), and then MeOH to afford eight fractions (Fr.1--Fr.8) on the basis of TLC analysis. Fr.5 was applied over CC of silica gel with PE--EtOAc (PE, 70%--0) to afford three sub-fractions (Fr.5-1--Fr.5-3). Fr.5-3 was then subjected to Sephadex LH-20 CC and eluted with a mixture of CH~2~Cl~2~--MeOH (*v:v*, 1:1) to obtain two sub-fractions (Fr.5-3-1--Fr.5-3-2). Fr.5-3-1 was then repeatedly separated by silica gel and ODS column chromatography, and then purified by HPLC (MeOH--H~2~O, 75--25) to afford Compounds **1** (3 mg) and **2** (2 mg).

Aspersymmetide A (**1**): white powder; $\left\lbrack \alpha \right\rbrack_{D}^{24}$ −174.2 (*c* 0.80, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 206 (4.01), 227 (3.90), 271 (3.34) nm; IR (KBr) ν~max~ 3441, 1632, and 1399 cm^−1^; ^1^H and ^13^C NMR see [Table 1](#marinedrugs-15-00363-t001){ref-type="table"}; ESI MS^2^ (fragmentation of *m*/*z* 727.52 \[M + H\]^+^) *m*/*z* 580.25 \[M − Phe + H\]^+^, 511.23 \[M − Pro − AA + H\]^+^, 461.22 \[M − Phe − AA + H\]^+^, 364.16 \[M − Pro − AA − Phe + H\]^+^, 267.11 \[M − Pro − AA − Phe − Pro + H\]^+^, 217.10 \[M − Phe − AA − Pro − Phe + H\]^+^; HRESIMS *m*/*z* 727.3245 \[M + H\]^+^, 749.3062 \[M + Na\]^+^ (calcd. for C~42~H~43~N~6~O~6~, 727.3239 \[M + H\]^+^, C~42~H~42~N~6~O~6~Na, 749.3058 \[M + Na\]^+^).

The structure of **2** was assigned by spectroscopic method and comparison of the ^1^H- and ^13^C-NMR data (see [Supplementary Information](#app1-marinedrugs-15-00363){ref-type="app"}) with those reported in the literature \[[@B20-marinedrugs-15-00363]\].

3.4. Acid Hydrolysis and Marfey's Analysis of ***1*** {#sec3dot4-marinedrugs-15-00363}
-----------------------------------------------------

A solution of **1** (0.5 mg) with HCl (6 M, 1 mL) was hydrolyzed by heating for 20 h at 110 °C. The solution was evaporated to dryness under vacuum and redissolved in H~2~O (250 μL). The acid hydrolysate solution (50 μL) was treated with 1% solution of [l]{.smallcaps}-FDAA (20 μL) in acetone followed by a solution of NaHCO~3~ (1 M, 10 μL). The mixture was heated at 40 °C for 1 h. The reaction was stopped by HCl (2 M, 5 μL). The standards of amino acids ([l]{.smallcaps}-Pro, [l]{.smallcaps}/[d]{.smallcaps}-Pro, [l]{.smallcaps}-Phe, and [l]{.smallcaps}/[d]{.smallcaps}-Phe) were derivatized with [l]{.smallcaps}-FDAA in the same manner as that of **1**. All [l]{.smallcaps}-FDAA derivatives were analyzed and detected by UPLCMS (ACQUITY UPLC^®^ (Waters Ltd., Boston, MA, USA)) BEH C18, 2.1 × 50 mm, 1.7 μm; solvents: MeCN (A), H~2~O (0.1% HCOOH) (B); linear gradient: 0--13 min, 5--50% A; 13--15 min, 50--100% A; 15--17 min, 100% A; 17--18 min, 100--5% A; 18--20 min, 5% A; flow rate: 0.5 mL/min; monitor: 190--700 nm; ESI MS scan: 150--1000 Da). Retention times (min) and ESI MS of the amino acid derivatives were recorded as follows: [l]{.smallcaps}-FDAA--[l]{.smallcaps}-Pro 6.24 min, [l]{.smallcaps}-FDAA--[d]{.smallcaps}-Pro 6.81 min (*m*/*z* 367.1 \[M − H\]^−^), [l]{.smallcaps}-FDAA--[l]{.smallcaps}-Phe 8.92 min, [l]{.smallcaps}-FDAA--[d]{.smallcaps}-Phe 9.99 min (*m*/*z* 417.1 \[M − H\]^−^) ([Figure S14](#app1-marinedrugs-15-00363){ref-type="app"}).

3.5. Biological Assay {#sec3dot5-marinedrugs-15-00363}
---------------------

Brine shrimp lethality against *Artemia salina* was evaluated using the modified Reed-Muench method \[[@B45-marinedrugs-15-00363]\], with doxorubicin as a positive control \[[@B46-marinedrugs-15-00363]\]. Cytotoxic activity was evaluated against the MCF-7, NCI-H292, and A-431 cell lines by the MTT method \[[@B47-marinedrugs-15-00363]\], with adriamycin as a positive control. Antibacterial activity against *S. albus* and *E. coli* was evaluated by using 96-well microtiter plates \[[@B48-marinedrugs-15-00363]\], with ciprofloxacin as a positive control. Antiviral activity against HCMV and HSV-1 was evaluated by the cytopathic effect (CPE) inhibition assay by the MTT method \[[@B47-marinedrugs-15-00363]\], with cidofovir and acyclovir as positive controls, respectively. AChE inhibition was determined spectrophotometrically using acetylthiocholine iodide (ATCI) as substrate by modified Ellman method \[[@B49-marinedrugs-15-00363]\], with huperzine A and galantamine hydrobromide as positive controls. Top I inhibiting activity was tested on the basis of DNA relaxation experiment \[[@B50-marinedrugs-15-00363]\], with 10-hydroxy camptothecin (OPT) as a positive control. *α*-Glucosacharase inhibiting activity was evaluated by the Dewi's method \[[@B51-marinedrugs-15-00363]\], with acarbose as a positive control.

4. Conclusions {#sec4-marinedrugs-15-00363}
==============

A new centrosymmetric cyclopeptide, aspersymmetide A (**1**), was obtained from the gorgonian-derived fungal strain *Aspergillus versicolor* (TA01-14). Compound **1** represents the first example of marine-derived centrosymmetric cyclohexapeptide with weak cytotoxicity.
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marinedrugs-15-00363-t001_Table 1

###### 

^1^H and ^13^C NMR (500 and 125 MHz, DMSO-*d*~6~) of aspersymmetide A (**1**).

  ----------------------------------------------------------------
  Position   *δ*~H~, Mult. (*J* in Hz)   *δ*~C~, Type   
  ---------- --------------------------- -------------- ----------
  Pro.       1                                          169.8, C

  2          4.47, d (8.0)               60.5, CH       

  3          Ha 2.21, m\                 31.4, CH~2~    
             Hb 1.72, m                                 

  4          Ha 1.86, m\                 20.9, CH~2~    
             Hb 1.68, m                                 

  5          Ha 3.52, dd (11.5, 8.5)\    46.7, CH~2~    
             Hb 3.40, dd (11.5, 10.2)                   

  AA         7                                          167.1, C

  8                                      115.1, C       

  9          7.89, d (8.0)               127.5, CH      

  10         6.83, t (8.0)               121.2, CH      

  11         6.91, t (8.0)               132.0, CH      

  12         7.74, d (8.0)               117.9, CH      

  13                                     140.2, C       

  14 (NH)    12.23, br s                                

  Phe.       15                                         168.4, C

  16         5.24, m                     51.6, CH       

  17         Ha 3.21, dd (13.6, 5.1)\    37.2, CH~2~    
             Hb 2.87, dd (13.6, 9.5)                    

  18                                     138.3, C       

  19/23      7.19, d (7.3)               129.6, CH      

  20/22      7.10, t (7.3)               127.6, CH      

  21         7.03, t (7.3)               125.8, CH      

  24 (NH)    9.10, d (9.0)                              
  ----------------------------------------------------------------

marinedrugs-15-00363-t002_Table 2

###### 

Natural products of centrosymmetric cyclopeptides (CSCs).

  Compd.                    Collected Source         Biosynthetic Source                                           Bioactivity                                                                               Reference
  ------------------------- ------------------------ ------------------------------------------------------------- ----------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------
  Enniatin A (**3**)        Fungus                   *Fusarium* sp.                                                Anti-mycotoxigenic fungi                                                                  \[[@B22-marinedrugs-15-00363],[@B30-marinedrugs-15-00363],[@B31-marinedrugs-15-00363]\]
  Enniatin B (**4**)        *Verticillium* sp.       \[[@B22-marinedrugs-15-00363],[@B32-marinedrugs-15-00363]\]                                                                                             
  Enniatin C (**5**)        *Verticillium* sp.       \[[@B22-marinedrugs-15-00363],[@B32-marinedrugs-15-00363]\]                                                                                             
  Enniatin MK1688 (**6**)   *Fusarium oxysporum*     \[[@B22-marinedrugs-15-00363],[@B33-marinedrugs-15-00363]\]                                                                                             
  Verticilide B1 (**7**)    *Verticillium* sp.       Acyl-CoA:cholesterol acyltransferase inhibition               \[[@B34-marinedrugs-15-00363]\]                                                           
  Himastatin (**8**)        Actinomycete             *Streptomyces hygroscopicus*                                  Cytotoxic activity                                                                        \[[@B35-marinedrugs-15-00363],[@B36-marinedrugs-15-00363],[@B37-marinedrugs-15-00363]\]
  Beauvericin (**9**)       Fungus                   *Fusarium oxysporum*                                          Cytotoxic and antiangiogenic activities                                                   \[[@B38-marinedrugs-15-00363]\]
  Hirsutellide A (**10**)   *Hirsutella kobayasii*   Antibacterial and antimalarial activities                     \[[@B39-marinedrugs-15-00363]\]                                                           
  Verticilide A1 (**11**)   *Verticillium* sp.       Acyl-CoA:cholesterol acyltransferase inhibition               \[[@B34-marinedrugs-15-00363]\]                                                           
  Bassianolide (**12**)     *Beauveria bassiana*     Insecticidal activity                                         \[[@B41-marinedrugs-15-00363],[@B42-marinedrugs-15-00363],[@B43-marinedrugs-15-00363]\]   
  PF1022A (**13**)          *Ascaridia galli*        Anthelmintic activity                                         \[[@B25-marinedrugs-15-00363]\]                                                           
  Thiocoraline (**14**)     Actinomycete             *Micromonospora* sp.                                          Cytotoxic and antimicrobial activities                                                    \[[@B44-marinedrugs-15-00363]\]
